Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient (API) supporting its lead oncology candidate, ONC010. The program was conducted in collaboration with Dalton Pharma Services and establishes a qualified reference standard to support analytical testing, manufacturing consistency, quality control, and future regulatory and clinical activities.
This milestone bolsters the company’s chemistry, manufacturing, and controls (CMC) framework, following recent progress in API manufacturing, precursor scale-up, analytical method development, and chiral purity testing. Onco-Innovations noted that the reference standard program is integral to its broader strategy of advancing ONC010 toward clinical readiness, while ongoing analytical development efforts continue across stability testing, impurity profiling, formulation characterization, and quality control systems.
The completion of the reference standard is a critical step in ensuring the quality and reproducibility of ONC010, a candidate targeting solid tumors. The company has secured an exclusive worldwide license to patented technology for this indication, positioning it to address significant unmet medical needs in oncology.
For more details, the full press release is available at https://ibn.fm/EefIN. Additional updates on Onco-Innovations can be accessed via their newsroom at https://ibn.fm/ONNVF.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions.
